UA106877C2 - Фармацевтична композиція ентакапону або його солей пролонгованого вивільнення - Google Patents

Фармацевтична композиція ентакапону або його солей пролонгованого вивільнення

Info

Publication number
UA106877C2
UA106877C2 UAA201103384A UAA201103384A UA106877C2 UA 106877 C2 UA106877 C2 UA 106877C2 UA A201103384 A UAA201103384 A UA A201103384A UA A201103384 A UAA201103384 A UA A201103384A UA 106877 C2 UA106877 C2 UA 106877C2
Authority
UA
Ukraine
Prior art keywords
entacapone
salts
pharmaceutical composition
extended release
release pharmaceutical
Prior art date
Application number
UAA201103384A
Other languages
English (en)
Russian (ru)
Inventor
Рітеш Капур
Муніш Талвар
Санджай МАТЕ
Манодж МАШАЛКАР
Гіріш Кумар Джаін
Мандар КОДГУЛЕ
Original Assignee
Вокхардт Рісерч Сентер
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41279194&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA106877(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Вокхардт Рісерч Сентер filed Critical Вокхардт Рісерч Сентер
Publication of UA106877C2 publication Critical patent/UA106877C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Винахід стосується фармацевтичної композиції пролонгованого вивільнення, що містить від приблизно 200 до приблизно 1000 мг ентакапону або його солей, при цьому ентакапон покритий одним або декількома гідрофільними або гідрофобними полімерами або впроваджений в матрицю, яка містить один або декілька гідрофільних або гідрофобних полімерів для досягнення пролонгованого вивільнення, необов'язково з іншими фармацевтично прийнятними ексципієнтами, та способу її отримання.
UAA201103384A 2008-08-22 2009-08-22 Фармацевтична композиція ентакапону або його солей пролонгованого вивільнення UA106877C2 (uk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1777MU2008 2008-08-22
IN1778MU2008 2008-08-22
PCT/IB2009/053698 WO2010020969A1 (en) 2008-08-22 2009-08-22 An extended release pharmaceutical composition of entacapone or salts thereof

Publications (1)

Publication Number Publication Date
UA106877C2 true UA106877C2 (uk) 2014-10-27

Family

ID=41279194

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201103384A UA106877C2 (uk) 2008-08-22 2009-08-22 Фармацевтична композиція ентакапону або його солей пролонгованого вивільнення

Country Status (15)

Country Link
US (2) US9289392B2 (uk)
EP (1) EP2328565B1 (uk)
KR (1) KR101667762B1 (uk)
CN (1) CN102170870A (uk)
AU (1) AU2009283813B2 (uk)
BR (1) BRPI0916922A2 (uk)
CA (1) CA2734972C (uk)
ES (1) ES2476765T3 (uk)
IL (1) IL211344A0 (uk)
MX (1) MX2011002017A (uk)
NZ (1) NZ591326A (uk)
RU (1) RU2540465C2 (uk)
UA (1) UA106877C2 (uk)
WO (1) WO2010020969A1 (uk)
ZA (1) ZA201101439B (uk)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA026419B1 (ru) * 2010-03-04 2017-04-28 Орион Корпорейшн Применение леводопы, карбидопы и энтакапона для лечения болезни паркинсона
WO2012147099A1 (en) * 2011-04-25 2012-11-01 Suven Nishtaa Pharma Pvt. Ltd. Pharmaceutical compositions of levodopa, carbidopa and entacapone
CN103476406B (zh) * 2011-04-26 2017-05-24 因华生技制药股份有限公司 安它可朋组合物
WO2014037832A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment of epilepsy and neurological diseases
US9399634B2 (en) 2012-05-07 2016-07-26 Cellix Bio Private Limited Compositions and methods for the treatment of depression
WO2013168021A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
CA2872975A1 (en) 2012-05-07 2013-11-14 Cellixbio Private Limited Compositions and methods for the treatment of neurological disorders
WO2013168023A1 (en) * 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of parkinson's disease
WO2013167992A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of inflammatory disorders
WO2013167993A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological degenerative disorders
WO2013168025A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of blood clotting disorders
WO2013167991A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic disorders
US9573927B2 (en) 2012-05-10 2017-02-21 Cellix Bio Private Limited Compositions and methods for the treatment of severe pain
WO2013168002A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological conditions
US9339484B2 (en) 2012-05-10 2016-05-17 Cellix Bio Private Limited Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
WO2013168001A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
US9403857B2 (en) 2012-05-10 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
WO2013168011A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of chronic pain
WO2013168014A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of familial amyloid polyneuropathy
WO2013168012A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
US9346742B2 (en) 2012-05-10 2016-05-24 Cellix Bio Private Limited Compositions and methods for the treatment of fibromyalgia pain
US9394288B2 (en) 2012-05-10 2016-07-19 Cellix Bio Private Limited Compositions and methods for the treatment of asthma and allergy
WO2013167999A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurologic diseases
US9315478B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
WO2013168033A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neurologic diseases
WO2013175347A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
WO2013175376A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of local pain
JP2015518854A (ja) 2012-05-23 2015-07-06 セリックスビオ プライヴェート リミテッド 多発性硬化症の治療のための組成物および方法
CA2873096A1 (en) 2012-05-23 2013-11-28 Cellixbio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
US9434729B2 (en) 2012-05-23 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
CN104583182A (zh) 2012-05-23 2015-04-29 塞利克斯比奥私人有限公司 用于治疗粘膜炎的组合物和方法
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
US9187427B2 (en) 2012-08-03 2015-11-17 Cellix Bio Private Limited N-substituted nicotinamide compounds and compositions for the treatment migraine and neurologic diseases
WO2014037833A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment inflammation and lipid disorders
SG11201407325YA (en) 2012-09-08 2014-12-30 Cellix Bio Private Ltd Compositions and methods for treatment of inflammation and lipid disorders
CN103845317B (zh) * 2012-11-28 2018-05-08 北京生命科学研究所 恩他卡朋在预防或治疗肥胖等代谢综合征中的应用
WO2014151742A1 (en) * 2013-03-15 2014-09-25 Mylan, Inc. Formulation containing carbidopa, levodopa, and entacapone
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
WO2014195961A1 (en) 2013-06-04 2014-12-11 Mahesh Kandula Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
SG11201706952VA (en) 2014-09-26 2017-10-30 Cellix Bio Private Ltd Compositions and methods for the treatment of epilepsy and neurological disorders
EP3201168B1 (en) 2014-09-29 2020-03-18 Cellix Bio Private Limited Compounds and compositions for the treatment of multiple sclerosis
EP3212626B1 (en) 2014-10-27 2018-11-07 Cellix Bio Private Limited Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
CN110845355A (zh) 2015-01-06 2020-02-28 塞尔利克斯生物私人有限公司 用于治疗炎症和疼痛的组合物和方法
WO2019191353A1 (en) * 2018-03-29 2019-10-03 Riverside Pharmaceuticals Corporation Levodopa fractionated dose composition and use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6599530B2 (en) * 1998-09-14 2003-07-29 Orion Corporation Oral compacted composition comprising catechol derivatives
US20080118556A1 (en) * 1998-11-02 2008-05-22 Elan Corporation, Plc Modified Release of Compositions Containing a Combination of Carbidopa, Levodopa and Entacapone
FI109453B (fi) * 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
ES2311442T3 (es) * 2005-06-08 2010-01-07 Orion Corporation Un metood para la fabricacion de granulos que contienen entacapona para formas de dosificacion oral.
US20070275060A1 (en) * 2005-08-05 2007-11-29 Osmotica Costa Rica Sociedad Anonima Extended release solid pharmaceutical composition containing carbidopa and levodopa
WO2007073702A2 (es) * 2005-12-29 2007-07-05 Osmotica Corp. Comprimido multicapa con combinación de triple liberación
WO2007113371A1 (en) * 2006-03-31 2007-10-11 Iprbox Oy Pharmaceutical composition and preparation method thereof
US8741342B2 (en) 2006-10-30 2014-06-03 Wockhardt Research Centre Pharmaceutical compositions comprising entacapone, levodopa, and carbidopa
PT2252284E (pt) * 2008-02-06 2011-08-23 Wockhardt Research Center COMPOSIÇÕES FARMACjUTICAS DE ENTACAPONE, LEVODOPA E CARBIDOPA COM BIODISPONIBILIDADE MELHORADA

Also Published As

Publication number Publication date
RU2011110765A (ru) 2012-09-27
IL211344A0 (en) 2011-05-31
ZA201101439B (en) 2012-04-25
MX2011002017A (es) 2011-05-19
BRPI0916922A2 (pt) 2015-11-24
WO2010020969A1 (en) 2010-02-25
CA2734972C (en) 2017-03-28
ES2476765T3 (es) 2014-07-15
US20110229561A1 (en) 2011-09-22
KR101667762B1 (ko) 2016-10-20
CA2734972A1 (en) 2010-02-25
RU2540465C2 (ru) 2015-02-10
AU2009283813B2 (en) 2015-02-19
AU2009283813A1 (en) 2010-02-25
NZ591326A (en) 2012-12-21
EP2328565A1 (en) 2011-06-08
US9289392B2 (en) 2016-03-22
CN102170870A (zh) 2011-08-31
US20160015645A1 (en) 2016-01-21
KR20110046554A (ko) 2011-05-04
EP2328565B1 (en) 2014-06-04

Similar Documents

Publication Publication Date Title
UA106877C2 (uk) Фармацевтична композиція ентакапону або його солей пролонгованого вивільнення
WO2008053297A3 (en) Pharmaceutical compositions comprising entacapone, levodopa, and carbidopa
ZA201005615B (en) Pharmaceutical compositions of entacapone,levodopa and carbidopa with improved bioavailability
MX2010014234A (es) Compuestos pirazol 436.
WO2009063222A3 (en) Solid compositions
MX2009012030A (es) Formas farmacéuticas sólidas compuestas de un recubrimiento enterico con liberación acelerada del medicamento.
JO2973B1 (en) Fumarate salt for (alpha-beta-R) -6-bromo-alpha-[2- (methylamino) ethyl-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinoline ethanol
MX2010002210A (es) Derivados de catecolamina y profarmacos de los mismos.
EA201291089A1 (ru) Способ получения фармацевтических препаратов, предназначенных для перорального введения, содержащих один или более активных ингредиентов, и содержащих их композиций
WO2011023367A3 (en) Bisphosphonate-prodrugs
GB0606212D0 (en) Pharmaceutical compositions
ZA201003380B (en) Improved pharmaceutical composition containing a pyrrolidone anticonvulsant agent and methhod for the preparation thereof
UA93355C2 (uk) Композиція субероїланілід-гідроксамінової кислоти і способи її отримання
UA102111C2 (uk) Фармацевтична композиція у вигляді разової пероральної дози, що містить леводопу, карбідопу і ентакапон або їх солі
MY144613A (en) Formulations of suberoylanilide hydroxamic acid and methods for producing same
TW201129386A (en) Microcrystalline cellulose and calcium phosphate compositions useful as pharmaceutical excipients
WO2008057464A3 (en) Compositions and methods for improving the bioavailability of liothyronine
UA101627C2 (uk) Покривна композиція, що містить полідекстрозу, спосіб її одержання і застосування для нанесення покриття на тверді форми для перорального прийому
WO2008039894A3 (en) Atorvastatin pharmaceutical compositions
WO2007110765A3 (en) Processes for the preparation of octreotide
WO2005079753A3 (en) Extended release pharmaceutical compositions of divalproex sodium
MX2010008707A (es) Composiciones farmaceuticas de entacapona comicronizada con alcoholes de azucar.
MX2010008923A (es) Compuesto (r)-n*6*-etil-6,7-dihidro-5h-indeno(5,6-d)tiazol-2,6-dia mina y su uso como antipsicotico.
GEP20135819B (en) 3-(2,2,2-trimethylhydrazinium) propionate dihydrate composition of local administration
MX2009012429A (es) Composicion util para la prevencion de efectos adversos debido al uso de agonistas ppar-gamma.